<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Atenolol,Atenolol.png,Beta blockers,Beta blockers,1976,2006,ACE Inhibitor,ACE inhibitor,ATC code C07,Acebutolol,Activated charcoal" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Atenolol - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Atenolol</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../a/t/e/Image%7EAtenolol.png_29d7.html" class="image" title=""><img src="../../../upload/shared/thumb/7/70/Atenolol.png/220px-Atenolol.png" alt="" width="220" height="97" longdesc="../../../a/t/e/Image%7EAtenolol.png_29d7.html" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Atenolol</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">2-[4-[2-hydroxy-3-(1-methylethylamino<br />
)propoxy]phenyl]ethanamide</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=29122-68-7&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=29122-68-7&amp;rn=1" rel="nofollow">29122-68-7</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="../../../a/t/c/ATC_code_C07_0a08.html" title="ATC code C07">C07</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=C07AB03" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=C07AB03" rel="nofollow">AB03</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2249" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2249" rel="nofollow">2249</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../d/r/u/DrugBank_2050.html" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00172" class="external text" title="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00172" rel="nofollow">APRD00172</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>14</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(154,154,154); font-weight: bold;">H</span></a><sub>22</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(000,000,255); font-weight: bold;">N</span></a><sub>2</sub><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(232,070,070); font-weight: bold;">O</span></a><sub>3</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">266.336 g/mol</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">40-50%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/l/a/Plasma_protein_binding.html" title="Plasma protein binding">Protein binding</a></td>
<td bgcolor="#EEEEEE">6-16%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE"><a href="../../../l/i/v/Liver.html" title="Liver">Hepatic</a> &lt;10%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">6-7hours</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE"><a href="../../../k/i/d/Kidney.html" title="Kidney">Renal</a><br />
<a href="../../../m/a/m/Mammary_gland.html" title="Mammary gland">Lactic</a> (In lactiferous females)</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>C<small>(<a href="../../../a/u/s/Australia.html" title="Australia">AU</a>)</small> D<small>(<a href="../../../u/n/i/United_States_09d4.html" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p><span class="Unicode">℞</span> P<small>rescription only</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">oral <a href="../../../i/n/t/Intravenous.html" title="Intravenous">iv</a></td>
</tr>
</table>
<p><b>Atenolol</b> is a drug belonging to the group of <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">beta blockers</a>, a class of drugs used primarily in <a href="../../../c/a/r/Cardiovascular_disease.html" title="Cardiovascular disease">cardiovascular diseases</a>. Introduced in <a href="../../../1/9/7/1976.html" title="1976">1976</a>, atenolol was developed as a replacement for <a href="../../../p/r/o/Propranolol.html" title="Propranolol">propranolol</a> in the treatment of <a href="../../../h/y/p/Hypertension.html" title="Hypertension">hypertension</a>. Hypertension is a clinical condition in which the arterial <a href="../../../b/l/o/Blood_pressure.html" title="Blood pressure">blood pressure</a> in rest exceeds constantly 140/90 mm Hg (as defined by the <a href="../../../w/o/r/World_Health_Organization_57ba.html" title="World Health Organization">World Health Organization</a>). Hypertension is a risk factor for <a href="../../../s/t/r/Stroke.html" title="Stroke">stroke</a>, <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> (heart attack), and serious renal damage.</p>
<p>Propranolol is known to readily cross the <a href="../../../b/l/o/Blood-brain_barrier.html" title="Blood-brain barrier">blood-brain barrier</a> (BBB) and can pass into the brain, causing side-effects such as <a href="../../../c/l/i/Clinical_depression.html" title="Clinical depression">depression</a> and nightmares; atenolol was specifically developed to be unable to pass through the blood-brain barrier in order to prevent this effect.</p>
<p>Whilst atenolol, the most widely used beta-blocker in the <a href="../../../u/n/i/United_Kingdom_5ad7.html" title="United Kingdom">United Kingdom</a>, was once first-line treatment for hypertension, the role for beta-blockers in hypertension was downgraded in June 2006 in the United Kingdom to fourth-line as they perform less well than other drugs, particularly in the elderly, and there is increasing evidence that the most frequently used beta-blockers at usual doses carry an unacceptable risk of provoking <a href="../../../d/i/a/Diabetes_mellitus_type_2.html" title="Diabetes mellitus type 2">type 2 diabetes</a>.<sup id="_ref-NHSnews_0" class="reference"><a href="#_note-NHSnews" title="">[1]</a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">1</span> <span class="toctext">Indications</span></a></li>
<li class="toclevel-1"><a href="#Pharmacokinetic_data"><span class="tocnumber">2</span> <span class="toctext">Pharmacokinetic data</span></a></li>
<li class="toclevel-1"><a href="#Contraindications"><span class="tocnumber">3</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1"><a href="#Side_effects"><span class="tocnumber">4</span> <span class="toctext">Side effects</span></a></li>
<li class="toclevel-1"><a href="#Interactions"><span class="tocnumber">5</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1"><a href="#Dosage"><span class="tocnumber">6</span> <span class="toctext">Dosage</span></a></li>
<li class="toclevel-1"><a href="#Combination_treatment_of_hypertension"><span class="tocnumber">7</span> <span class="toctext">Combination treatment of hypertension</span></a></li>
<li class="toclevel-1"><a href="#Overdose"><span class="tocnumber">8</span> <span class="toctext">Overdose</span></a></li>
<li class="toclevel-1"><a href="#Footnotes"><span class="tocnumber">9</span> <span class="toctext">Footnotes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">10</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases such as <a href="../../../h/y/p/Hypertension.html" title="Hypertension">hypertension</a>, <a href="../../../c/o/r/Coronary_heart_disease.html" title="Coronary heart disease">coronary heart disease</a>, <a href="../../../a/r/r/Arrhythmia.html" title="Arrhythmia">arrhythmias</a>, and treatment of <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> after the acute event. Patients with compensated <a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">congestive heart failure</a> may be treated with atenolol as a comedication (usually together with an <a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="ACE inhibitor">ACE inhibitor</a>, a <a href="../../../d/i/u/Diuretic.html" title="Diuretic">diuretic</a> and a <a href="../../../d/i/g/Digitalis.html" title="Digitalis">digitalis</a>-glycoside, if indicated). In patients with congestive heart failure, it reduces the need for and the consumption of <a href="../../../o/x/y/Oxygen.html" title="Oxygen">oxygen</a> of the heart muscle. It is very important to start with low doses, as atenolol reduces also the muscular power of the heart, which is an undesired effect in congestive heart failure.</p>
<p>The drug is also used to treat other conditions, including <a href="../../../d/y/s/Dysautonomia.html" title="Dysautonomia">dysautonomia</a>, <a href="../../../a/n/x/Anxiety.html" title="Anxiety">anxiety</a> and <a href="../../../h/y/p/Hyperthyroidism.html" title="Hyperthyroidism">hyperthyroidism</a> (overfunction of the <a href="../../../t/h/y/Thyroid.html" title="Thyroid">thyroid</a> gland).</p>
<p>Due to its hydrophilic properties, the drug is less suitable in <a href="../../../m/i/g/Migraine.html" title="Migraine">migraine</a> prophylaxis compared to propranolol, because for this indication, atenolol would have to reach the brain in high concentrations, which is not the case (see below).</p>
<p>Atenolol is a so-called beta1-selective (or 'cardioselective') drug. That means that it exerts greater blocking activity on myocardial beta1-receptors than on beta2 ones in the lung. The beta2 receptors are responsible to keep the bronchial system open. If these receptors are blocked, bronchospasm with serious lack of oxygen in the body can result. However, due to its cardioselective properties, the risk of bronchospastic reactions if using atenolol is reduced compared to nonselective drugs as <a href="../../../p/r/o/Propranolol.html" title="Propranolol">propranolol</a>. Nonetheless, this reaction may also be encountered with atenolol, particularly with high doses. Extreme caution should be exerted if atenolol is given to <a href="../../../a/s/t/Asthmatic.html" title="Asthmatic">asthma</a> patients, who are particularly at risk; the dose should be as low as possible. If an asthma attack occurs, the inhalation of a beta2-mimetic antiasthmatic, such as hexoprenalin or <a href="../../../s/a/l/Salbutamol.html" title="Salbutamol">salbutamol</a>, will usually suppress the symptoms.</p>
<p>Provisional data suggests that antihypertensive therapy with atenolol provides weaker protective action against cardiovascular complications (e.g. myocardial infarction and <a href="../../../s/t/r/Stroke.html" title="Stroke">stroke</a>) compared to other antihypertensive drugs. In particular, <a href="../../../d/i/u/Diuretic.html" title="Diuretic">diuretics</a> are superior. Propranolol and <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">metoprolol</a> might also be better alternatives. However, controlled studies are lacking (CARLBERG, B. et al.: Lancet 2004; 364: 1684-9).</p>
<p>Unlike most other commonly-used beta blockers, atenolol is excreted almost exclusively by the <a href="../../../k/i/d/Kidney.html" title="Kidney">kidneys</a>. This makes it attractive for use in individuals with end-stage <a href="../../../l/i/v/Liver.html" title="Liver">liver</a> disease.</p>
<p><a name="Pharmacokinetic_data" id="Pharmacokinetic_data"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Pharmacokinetic data">edit</a>]</span> <span class="mw-headline">Pharmacokinetic data</span></h2>
<ul>
<li>t<sub>cmax</sub> = 2 to 4 hours after oral dosing (time elapsed before maximal concentration in the <a href="../../../b/l/o/Blood_plasma.html" title="Blood plasma">blood plasma</a> is reached)</li>
<li>The mean elimination <a href="../../../h/a/l/Halflife.html" title="Halflife">halflife</a> is 6 hours. However, the action of an usual oral dose of 25 to 100 mg lasts over a period of 24 hours.</li>
<li>Atenolol is a hydrophilic drug. The concentration found in brain tissue is approximately 15% of the plasma concentration only. The drug crosses the <a href="../../../p/l/a/Placenta.html" title="Placenta">placenta</a> barrier freely. In the milk of <a href="../../../b/r/e/Breastfeeding.html" title="Breastfeeding">breastfeeding</a> mothers, approximately 3 times the plasma concentrations are measured.</li>
<li>Atenolol is almost exclusively eliminated renally and is well removable by <a href="../../../d/i/a/Dialysis.html" title="Dialysis">dialysis</a>. A compromised <a href="../../../l/i/v/Liver.html" title="Liver">liver</a> function does not lead to higher peak-activity and/or a longer halflife with possible accumulation. However, preexisting renal insufficience of higher degree makes dose-reductions necessary (see below) in order to avoid overdose.</li>
</ul>
<p><a name="Contraindications" id="Contraindications"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Contraindications">edit</a>]</span> <span class="mw-headline">Contraindications</span></h2>
<ul>
<li><a href="../../../b/r/a/Bradycardia.html" title="Bradycardia">bradycardia</a> (pulse less than 50 bpm)</li>
<li>cardiogenic shock</li>
<li><a href="../../../a/s/t/Asthma.html" title="Asthma">asthma</a> (may cause broncho-constriction)</li>
<li>symptomatic hypotension (blood pressure of less than 100/60 mm Hg with dizziness, vertigo etc.)</li>
<li>angina of the Prinzmetal type (vasospastic angina)</li>
<li>metabolic acidosis (a severe condition with a more acid blood than normal)</li>
<li>severe disorders in perpheral arterial circulation</li>
<li>AV-Blockage of second and third degree (a particular form of <a href="../../../a/r/r/Arrhythmia.html" title="Arrhythmia">arrhythmia</a>)</li>
<li>acutely decompensated congestive heart failure (symptoms may be fluid retention with peripheral <a href="../../../e/d/e/Edema.html" title="Edema">edema</a> and/or abdominal fluid retention (ascites), and/or lung edema)</li>
<li><a href="../../../s/i/c/Sick_sinus_syndrome.html" title="Sick sinus syndrome">sick sinus syndrome</a> (a particular form of arrhythmia, very rarely encountered)</li>
<li>hypersensitivity and/or <a href="../../../a/l/l/Allergy.html" title="Allergy">allergy</a> to Atenolol</li>
<li>Caution: patients with preexisting asthma bronchiale</li>
<li>Caution: only if clearly needed during <a href="../../../p/r/e/Pregnancy.html" title="Pregnancy">pregnancy</a>, as atenolol may retard fetal growth and possibly causes other abnormalities. (If you are pregnant or plan to become pregnant, ask your doctor.)</li>
</ul>
<p><a name="Side_effects" id="Side_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Side effects">edit</a>]</span> <span class="mw-headline">Side effects</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../p/r/o/Propranolol.html" title="Propranolol">Propranolol</a></i></span></dd>
</dl>
<p>Atenolol causes significantly fewer central nervous system side effects (depressions, nightmares) and fewer bronchospastic reactions, both due to its particular pharmacologic profile.</p>
<p>It was the main beta-blocker identified as carrying a higher risk of provoking <a href="../../../d/i/a/Diabetes_mellitus_type_2.html" title="Diabetes mellitus type 2">type 2 diabetes</a>, leading to its downgrading in the United Kingdom in June 2006 to fourth-line agent in the management of hypertension.<sup id="_ref-NHSnews_1" class="reference"><a href="#_note-NHSnews" title="">[1]</a></sup></p>
<p>In addition, beta blockers blunt the usual sympathetic nervous system response to hypoglycemia (i.e. sweating, agitation, tachycardia). These drugs therefore have an ability to mask a dangerously low blood sugar, which further decreases their safety and utility in diabetic patients.</p>
<p><a name="Interactions" id="Interactions"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Interactions">edit</a>]</span> <span class="mw-headline">Interactions</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../p/r/o/Propranolol.html" title="Propranolol">Propranolol</a></i></span></dd>
</dl>
<p><a name="Dosage" id="Dosage"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Dosage">edit</a>]</span> <span class="mw-headline">Dosage</span></h2>
<p>In patients with normal renal function, the daily dose is 25 to 100 <a href="../../../m/i/l/Milligram.html" title="Milligram">mg</a> (in one dose or in two divided doses) depending on the indication and severity of the disease. In most patients, the physician will start with a low initial dose and make increments in weekly intervals as tolerated.</p>
<p>In patients with chronic heart failure the initial dose should be particularly low and increments should be made slowly.</p>
<p>In patients with a creatinin-clearance (an indicator for renal function) less than (35 ml/min) /1.73 m² the daily dose should be reduced to 25 to 50 mg daily according to the clinical response of the individual patient. If a patient with end-stage renal failure is scheduled on regular dialysis, usually 50 mg are given after each dialysis procedure. In these patients, a severe hypotension may occur afterwards.</p>
<p><a name="Combination_treatment_of_hypertension" id="Combination_treatment_of_hypertension"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Combination treatment of hypertension">edit</a>]</span> <span class="mw-headline">Combination treatment of hypertension</span></h2>
<p>If atenolol alone fails to control arterial hypertension, the drug can be combined with a diuretic and/or a vasodilator (<a href="../../../h/y/d/Hydralazine.html" title="Hydralazine">hydralazine</a>, or in severe cases <a href="../../../m/i/n/Minoxidil.html" title="Minoxidil">minoxidil</a>). Central alpha-agonists (e.g. <a href="../../../c/l/o/Clonidine.html" title="Clonidine">clonidine</a>), <a href="../../../a/c/e/ACE_Inhibitor_ced6.html" title="ACE Inhibitor">ACE Inhibitors</a> or AT-Antagonists such as losartan can also be given additionally. Exert caution with calcium-antagonists of the verapamile-type as adjunct therapy because of additional negative impact on the muscular strength of the heart. Use of calcium-antagonists of the <a href="../../../n/i/f/Nifedipine.html" title="Nifedipine">nifedipine</a>-type is controversial.</p>
<p><a name="Overdose" id="Overdose"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Overdose">edit</a>]</span> <span class="mw-headline">Overdose</span></h2>
<p>Symptoms of <a href="../../../o/v/e/Overdose.html" title="Overdose">overdose</a> are due to excessive pharmacodynamic actions on beta1 and also beta2-receptors. These include <a href="../../../b/r/a/Bradycardia.html" title="Bradycardia">bradycardia</a>, severe <a href="../../../h/y/p/Hypotension.html" title="Hypotension">hypotension</a> with <a href="../../../s/h/o/Shock_%28medical%29.html" title="Shock (medical)">shock</a>, acute <a href="../../../h/e/a/Heart_failure.html" title="Heart failure">heart failure</a>, <a href="../../../h/y/p/Hypoglycemia.html" title="Hypoglycemia">hypoglycemia</a> (= low blood sugar) and bronchospastic reactions. Treatment is largely symptomatic. Hospitalization and intensive monitoring is indicated. In early cases emesis can be induced. <a href="../../../a/c/t/Activated_charcoal.html" title="Activated charcoal">Activated charcoal</a> is useful to absorb the drug. <a href="../../../a/t/r/Atropine.html" title="Atropine">Atropine</a> will counteract bradycardia, <a href="../../../g/l/u/Glucagon.html" title="Glucagon">glucagon</a> helps with hypoglycemia, <a href="../../../d/o/b/Dobutamine.html" title="Dobutamine">dobutamine</a> can be given against hypotension and the inhalation of a beta2-mimetic as hexoprenalin or <a href="../../../s/a/l/Salbutamol.html" title="Salbutamol">salbutamol</a> will terminate bronchospasms.</p>
<p><a name="Footnotes" id="Footnotes"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: Footnotes">edit</a>]</span> <span class="mw-headline">Footnotes</span></h2>
<ol class="references">
<li id="_note-NHSnews">^ <a href="#_ref-NHSnews_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-NHSnews_1" title=""><sup><i><b>b</b></i></sup></a> Sheetal Ladva (28/06/2006). <a href="http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=567178" class="external text" title="http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=567178" rel="nofollow">NICE and BHS launch updated hypertension guideline</a>. <a href="../../../n/a/t/National_Institute_for_Health_and_Clinical_Excellence_6317.html" title="National Institute for Health and Clinical Excellence">National Institute for Health and Clinical Excellence</a>. Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../s/e/p/September_30.html" title="September 30">09-30</a>.</li>
</ol>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/e/Atenolol.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.atenolol.tk/" class="external text" title="http://www.atenolol.tk/" rel="nofollow">Atenolol</a>, <a href="http://www.chm.bris.ac.uk/motm/motm.htm" class="external text" title="http://www.chm.bris.ac.uk/motm/motm.htm" rel="nofollow">Molecule of the Month</a> (uses <a href="../../../m/a/c/Macromedia_Flash_1a63.html" title="Macromedia Flash">Macromedia Flash</a>).</li>
<li><a href="http://www.sunderland.ac.uk/~hs0dad/profile/atenolol/atenhmpg.htm" class="external text" title="http://www.sunderland.ac.uk/~hs0dad/profile/atenolol/atenhmpg.htm" rel="nofollow">Atenolol drug information</a></li>
</ul>
<table class="navbox collapsible" style="margin: auto;">
<tr>
<th colspan="2" style="text-align:center;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; float:left;width:6em;text-align:left;"><a href="../../../b/e/t/Template%7EBeta_blockers_5115.html" title="Template:Beta blockers"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../b/e/t/Template%7EBeta_blockers_5115.html" class="external text" title="http://en.wikipedia.org../../../b/e/t/Template%7EBeta_blockers_5115.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">Beta blockers</a> <a href="../../../a/t/c/ATC_code_C07_0a08.html" title="ATC code C07">(C07)</a></th>
</tr>
<tr>
<th style="">Non-selective β antagonists (<a href="../../../a/t/c/ATC_code_C07_0a08.html#C07AA_Beta_blocking_agents.2C_non-selective" title="ATC code C07">C07AA</a>)</th>
<td><a href="../../../m/e/t/Metipranolol.html" title="Metipranolol">Metipranolol</a>, <a href="../../../n/a/d/Nadolol.html" title="Nadolol">Nadolol</a>, <a href="../../../o/x/p/Oxprenolol.html" title="Oxprenolol">Oxprenolol</a>, <a href="../../../p/e/n/Penbutolol.html" title="Penbutolol">Penbutolol</a>, <a href="../../../p/i/n/Pindolol.html" title="Pindolol">Pindolol</a>, <a href="../../../p/r/o/Propranolol.html" title="Propranolol">Propranolol</a>, <a href="../../../t/i/m/Timolol.html" title="Timolol">Timolol</a>, <a href="../../../s/o/t/Sotalol.html" title="Sotalol">Sotalol</a></td>
</tr>
<tr>
<th style="">β<sub>1</sub> antagonists (<i>cardioselective</i>) (<a href="../../../a/t/c/ATC_code_C07_0a08.html#C07AB_Beta_blocking_agents.2C_selective" title="ATC code C07">C07AB</a>)</th>
<td><strong class="selflink">Atenolol</strong>, <a href="../../../a/c/e/Acebutolol.html" title="Acebutolol">Acebutolol</a>, <a href="../../../b/e/t/Betaxolol.html" title="Betaxolol">Betaxolol</a>, <a href="../../../b/i/s/Bisoprolol.html" title="Bisoprolol">Bisoprolol</a>, <a href="../../../e/s/m/Esmolol.html" title="Esmolol">Esmolol</a>, <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">Metoprolol</a>, <a href="../../../n/e/b/Nebivolol.html" title="Nebivolol">Nebivolol</a></td>
</tr>
<tr>
<th style="">Mixed α<sub>1</sub>/β antagonists (<a href="../../../a/t/c/ATC_code_C07_0a08.html#C07AG_Alpha_and_beta_blocking_agents" title="ATC code C07">C07AG</a>)</th>
<td><a href="../../../c/a/r/Carvedilol.html" title="Carvedilol">Carvedilol</a>, <a href="../../../l/a/b/Labetalol.html" title="Labetalol">Labetalol</a></td>
</tr>
</table>

<!-- 
Pre-expand include size: 41643 bytes
Post-expand include size: 14414 bytes
Template argument size: 5180 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/t/e/Atenolol.html">http://en.wikipedia.org../../../a/t/e/Atenolol.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../b/e/t/Category%7EBeta_blockers_59c7.html" title="Category:Beta blockers">Beta blockers</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/t/e/Atenolol.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/t/e/Talk%7EAtenolol_7625.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Atenolol">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../it/a/t/e/Atenololo.html">Italiano</a>
	      </li>
	      	      <li>
	      <a href="../../../../hu/a/t/e/Atenolol.html">Magyar</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/a/t/e/Atenolol.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/a/t/e/Atenolol.html">Português</a>
	      </li>
	      	      <li>
	      <a href="../../../../ru/%D0%B0/%D1%82/%D0%B5/%D0%90%D1%82%D0%B5%D0%BD%D0%BE%D0%BB%D0%BE%D0%BB.html">Русский</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 03:14, 29 March 2007 by Wikipedia user <a href="../../../i/c/e/User%7EIceCreamAntisocial_4a3d.html" title="User:IceCreamAntisocial">IceCreamAntisocial</a>. Based on work by Wikipedia user(s) <a href="../../../a/l/a/User%7EAlaibot_de3d.html" title="User:Alaibot">Alaibot</a>, <a href="../../../t/h/i/User%7EThijs%21bot_bdf4.html" title="User:Thijs!bot">Thijs!bot</a>, <a href="../../../f/v/a/User%7EFvasconcellos_4804.html" title="User:Fvasconcellos">Fvasconcellos</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../s/t/b/User%7ESTBotD_8c4f.html" title="User:STBotD">STBotD</a>, <a href="../../../g/e/n/User%7EGene_Nygaard_634f.html" title="User:Gene Nygaard">Gene Nygaard</a>, <a href="../../../g/a/l/User%7EGalaxiaad_9067.html" title="User:Galaxiaad">Galaxiaad</a>, Dyslexik, <a href="../../../t/a/c/User%7ETachikoma_4c40.html" title="User:Tachikoma">Tachikoma</a>, <a href="../../../d/a/v/User%7EDavidruben_76a6.html" title="User:Davidruben">Davidruben</a>, <a href="../../../k/e/t/User%7EKetiltrout_7f16.html" title="User:Ketiltrout">Ketiltrout</a>, <a href="../../../o/h/n/User%7EOhnoitsjamie_fc14.html" title="User:Ohnoitsjamie">Ohnoitsjamie</a>, Tybalt01, <a href="../../../c/o/p/User%7ECopperman_fb28.html" title="User:Copperman">Copperman</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, <a href="../../../k/p/j/User%7EKpjas_9cb5.html" title="User:Kpjas">Kpjas</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../g/e/e/User%7EGeeJo_c589.html" title="User:GeeJo">GeeJo</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../g/r/i/User%7EGrinBot_48c7.html" title="User:GrinBot">GrinBot</a>, <a href="../../../j/a/c/User%7EJacqui_M_e8a5.html" title="User:Jacqui M">Jacqui M</a>, <a href="../../../d/r/a/User%7EDramatic_bee8.html" title="User:Dramatic">Dramatic</a>, <a href="../../../s/a/n/User%7ESannse_0094.html" title="User:Sannse">Sannse</a>, <a href="../../../m/a/n/User%7EMani1_e14b.html" title="User:Mani1">Mani1</a>, <a href="../../../t/a/g/User%7ETagishsimon_49c0.html" title="User:Tagishsimon">Tagishsimon</a>, <a href="../../../w/o/r/User%7EWormRunner_5b32.html" title="User:WormRunner">WormRunner</a>, <a href="../../../y/u/r/User%7EYurik_8d9d.html" title="User:Yurik">Yurik</a>, <a href="../../../c/a/c/User%7ECacycle_6f2f.html" title="User:Cacycle">Cacycle</a>, <a href="../../../i/v/a/User%7EIvan_Svircevic_d28e.html" title="User:Ivan Svircevic">Ivan Svircevic</a>, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../s/v/e/User%7ESverdrup_2f1f.html" title="User:Sverdrup">Sverdrup</a> and <a href="../../../a/l/e/User%7EAlex.tan_6c56.html" title="User:Alex.tan">Alex.tan</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
